胶质母细胞瘤患者围手术期实验室检查的国际实践差异——一项回顾性队列研究
该回顾性队列研究纳入2005至2013年间按标准治疗管理的胶质母细胞瘤患者,比较美国布莱根妇女医院(BWH)与荷兰乌得勒支大学医学中心(UMCU)围手术期70天内的实验室检查使用情况。校正年龄、性别、IDH1状态、术后KPS评分、住院时长和生存状态后,BWH的采血次数和实验室检查次数分别为UMCU的3.7倍(p<0.001)和4.7倍(p<0.001);UMCU每患者估算中位实验室费用为82欧元,BWH为256欧元;BWH异常检验结果的似然比更低(OR 0.75,p<0.001),但先前检验结果也异常时OR为2.09(p<0.001)。作者认为BWH开具实验室检查的临床阈值明显更低。
要点
- BWH围手术期采血次数为UMCU的3.7倍(p<0.001),实验室检查次数为4.7倍(p<0.001)。
- 每患者估算中位实验室费用UMCU为82欧元,BWH为256欧元。
- BWH异常检验结果似然比更低(OR 0.75,p<0.001),先前结果异常时OR为2.09(p<0.001)。
核心结论
- 作者认为BWH相比UMCU开具实验室检查的临床阈值明显更低。
- 作者提出进一步研究实验室检查的临床后果可识别过度与不足使用、降低医疗费用并减少患者承受的不必要不适。
研究设计与样本
- 回顾性队列研究,纳入2005至2013年间按标准治疗管理的胶质母细胞瘤患者,比较美国布莱根妇女医院(BWH)与荷兰乌得勒支大学医学中心(UMCU)。
- 采用泊松回归模型比较围手术期70天内采血次数和实验室检查次数,并比较每患者估算实验室费用。
- 采用广义线性混合效应模型比较异常检验结果的似然比。
- 分析校正了年龄、性别、IDH1状态、术后KPS评分、住院时长和生存状态。
主要发现
- 校正后BWH围手术期采血次数为UMCU的3.7倍(p<0.001),实验室检查次数为UMCU的4.7倍(p<0.001)。
- 每患者估算中位实验室费用UMCU为82欧元,BWH为256欧元。
- BWH异常检验结果似然比更低(OR 0.75,p<0.001),但先前检验结果也异常时OR为2.09(p<0.001)。
关键数值与推荐
- 围手术期定义为70天。
- 采血次数BWH为UMCU的3.7倍(p<0.001),实验室检查次数BWH为UMCU的4.7倍(p<0.001)。
- 每患者估算中位实验室费用UMCU为82欧元,BWH为256欧元。
- 异常检验结果似然比BWH的OR为0.75(p<0.001),先前结果也异常时OR为2.09(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although standard-of-care has been defined for the treatment of glioblastoma patients, substantial practice variation exists in the day-to-day clinical management. This study aims to compare the use of laboratory tests in the perioperative care of glioblastoma patients between two tertiary academic centers-Brigham and Women's Hospital (BWH), Boston, USA, and University Medical Center Utrecht (UMCU), Utrecht, the Netherlands. METHODS: All glioblastoma patients treated according to standard-of-care between 2005 and 2013 were included. We compared the number of blood drawings and laboratory tests performed during the 70-day perioperative period using a Poisson regression model, as well as the estimated laboratory costs per patient. Additionally, we compared the likelihood of an abnormal test result using a generalized linear mixed effects model. RESULTS: After correction for age, sex, IDH1 status, postoperative KPS score, length of stay, and survival status, the number of blood drawings and laboratory tests during the perioperative period were 3.7-fold (p < 0.001) and 4.7-fold (p < 0.001) higher, respectively, in BWH compared to UMCU patients. The estimated median laboratory costs per patient were 82 euros in UMCU and 256 euros in BWH. Furthermore, the likelihood of an abnormal test result was lower in BWH (odds ratio [OR] 0.75, p < 0.001), except when the prior test result was abnormal as well (OR 2.09, p < 0.001). CONCLUSIONS: Our results suggest a substantially lower clinical threshold for ordering laboratory tests in BWH compared to UMCU. Further investigating the clinical consequences of laboratory testing could identify over and underuse, decrease healthcare costs, and reduce unnecessary discomfort that patients are exposed to.
引用
- Senders JT, Maas SLN, Draaisma K, et al. International practice variation in perioperative laboratory testing in glioblastoma patients-a retrospective cohort study. Acta Neurochir (Wien). 2022. PMID: 34997355. doi:10.1007/s00701-021-05090-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。